TCM
Tang Capital Management Portfolio holdings
AUM
$1.98B
This Quarter Return
-9.39%
1 Year Return
+21.62%
3 Year Return
+290.69%
5 Year Return
+284.46%
10 Year Return
+928.34%
AUM
$982M
AUM Growth
+$982M
(+2.2%)
Cap. Flow
+$152M
Cap. Flow
% of AUM
15.44%
Top 10 Holdings %
Top 10 Hldgs %
37.6%
Holding
143
New
43
Increased
39
Reduced
6
Closed
15
Top Buys
| 1 |
Dynavax Technologies
DVAX
|
$28.1M |
| 2 |
ANI Pharmaceuticals
ANIP
|
$19.1M |
| 3 |
Acadia Pharmaceuticals
ACAD
|
$15.9M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
$14.9M |
| 5 |
NVIDIA
NVDA
|
$13M |
Top Sells
Sector Composition
| 1 | Healthcare | 95.92% |
| 2 | Technology | 1.53% |
| 3 | Real Estate | 0.71% |
| 4 | Communication Services | 0.66% |
| 5 | Financials | 0.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Tarsus Pharmaceuticals
TARS
$2.47B
| $61.3M | 6.24% | 2,254,797 | – | – |
|
2
Evolus
EOLS
$494M
| $52.6M | 5.36% | 4,847,399 +700,000 | +17% | +$7.6M |
|
3
KalVista Pharmaceuticals
KALV
$678M
| $49.7M | 5.06% | 4,218,829 +93,484 | +2% | +$1.1M |
|
4
Mirum Pharmaceuticals
MIRM
$3.71B
| $44M | 4.48% | 1,287,107 +100,000 | +8% | +$3.42M |
|
5
AnaptysBio
ANAB
$569M
| $33.4M | 3.4% | 1,330,879 | – | – |
|
|
6
ANI Pharmaceuticals
ANIP
$2.03B
| $28.7M | 2.92% | 450,000 +300,000 | +200% | +$19.1M |
|
|
7
Dynavax Technologies
DVAX
$1.19B
| $28.1M | 2.86% | +2,500,000 | New | +$28.1M |
|
8
Eli Lilly
LLY
$657B
| $24.4M | 2.49% | 27,000 | – | – |
|
|
9
Acadia Pharmaceuticals
ACAD
$4.38B
| $24.4M | 2.48% | 1,500,000 +981,100 | +189% | +$15.9M |
|
10
Vaxcyte
PCVX
$4B
| $22.7M | 2.31% | 300,000 | – | – |
|
11
PTC Therapeutics
PTCT
$3.92B
| $21.4M | 2.18% | 700,000 | – | – |
|
|
ITCI
12
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $20.5M | 2.09% | 300,000 +150,000 | +100% | +$10.3M |
|
13
Altimmune
ALT
$338M
| $18.3M | 1.86% | 2,750,000 | – | – |
|
14
Viridian Therapeutics
VRDN
$1.5B
| $18.1M | 1.85% | 1,392,925 +700,000 | +101% | +$9.11M |
|
|
AVDL
15
Avadel Pharmaceuticals
AVDL
$1.43B
| $17.3M | 1.76% | 1,230,000 +182,725 | +17% | +$2.57M |
|
16
CRISPR Therapeutics
CRSP
$4.71B
| $17.1M | 1.74% | 316,500 +200,000 | +172% | +$10.8M |
|
17
Rocket Pharmaceuticals
RCKT
$354M
| $16.1M | 1.64% | 750,000 +90,000 | +14% | +$1.94M |
|
18
Cullinan Oncology
CGEM
$445M
| $16.1M | 1.64% | 921,138 +350,000 | +61% | +$6.1M |
|
19
Aurinia Pharmaceuticals
AUPH
$1.58B
| $15.9M | 1.62% | 2,779,500 +729,500 | +36% | +$4.17M |
|
20
GSK
GSK
$79.9B
| $15.4M | 1.57% | 400,000 +100,000 | +33% | +$3.85M |
|
|
21
Jazz Pharmaceuticals
JAZZ
$7.75B
| $14.9M | 1.52% | +140,000 | New | +$14.9M |
|
22
Atea Pharmaceuticals
AVIR
$267M
| $14.8M | 1.51% | 4,476,741 +400,000 | +10% | +$1.32M |
|
|
23
NVIDIA
NVDA
$4.24T
| $14.2M | 1.45% | 115,019 +105,019 | +1,050% | +$13M |
|
24
Immunocore
IMCR
$1.62B
| $13.7M | 1.4% | 405,600 | – | – |
|
|
LENZ
25
LENZ Therapeutics
LENZ
$1.1B
| $12.9M | 1.32% | 747,616 +200,000 | +37% | +$3.46M |
|